Ferric Carboxymaltose Injection [Ferinject]

DRUG4 trials

Sponsors

Sichuan Huiyu Pharmaceutical Co., Ltd, Fundación para la Investigación del Hospital Clínico de Valencia, AFT Pharmaceuticals, Ltd., University Hospital, Montpellier

Conditions

Acute Coronary Syndromes (ACS)AnaemiaElderly (People Aged 65 or More)Iron DeficienciesIron DeficiencyIron Deficiency Anemia (IDA)Restless Legs Syndrome (RLS)

Phase 1

Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia

CompletedNCT06080555

Sichuan Huiyu Pharmaceutical Co., LtdAnaemia, Iron Deficiency

Start: 2023-10-09End: 2024-03-22Updated: 2024-04-18

Phase 2

Intravenous Iron in the Management of Drug-resistant Restless Legs syndromeI

Not yet recruitingNCT07822607

University Hospital, MontpellierRestless Legs Syndrome (RLS)

Start: 2026-10-01End: 2030-10-01Target: 66Updated: 2026-09-16

Phase 3

A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency Anemia

Not yet recruitingNCT07687784

AFT Pharmaceuticals, Ltd.Iron Deficiency Anemia (IDA)

Start: 2026-12-01End: 2028-07-01Target: 1366Updated: 2026-08-20

Phase 4

Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome

RecruitingNCT07476859

Fundación para la Investigación del Hospital Clínico de ValenciaAcute Coronary Syndromes (ACS), Elderly (People Aged 65 or More), Iron Deficiencies

Start: 2026-03-05End: 2028-05-01Target: 538Updated: 2026-03-24